Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00215254 · ClinicalTrials.gov registry record · Phase 2

Quetiapine in Social Anxiety Disorder

A Phase 2 study, sponsored by Duke University.

Completed
Registry status
Phase 2
Development phase
15
Enrollment target

NCT00215254 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 15 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00215254, a Phase 2 study, has completed, sponsored by Duke University.

COMPLETED
Registry status
Phase 2
Development phase
15 participants
Enrollment target

Study Summary

The purpose of the study is to examine the effectiveness and tolerability of quetiapine for the treatment of social anxiety disorder (SAD). The hypothesis is that quetiapine will be effective and well-tolerated for patients with social anxiety disorder.

Interventions

  • DRUG quetiapine

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2004-03
Est. Completion 2006-02
Phase Phase 2

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT00215254

The ClinicalTrials.gov registry entry for NCT00215254 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which quetiapine is the first listed.

NCT00215254 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00215254 about?

NCT00215254 is a clinical study titled "Quetiapine in Social Anxiety Disorder". The purpose of the study is to examine the effectiveness and tolerability of quetiapine for the treatment of social anxiety disorder (SAD). The hypothesis is that quetiapine will be effective and well-tolerated for patients with social anxiety disorder.

What is the current status of trial NCT00215254?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2004-03. Estimated completion is 2006-02.

What interventions are being tested in trial NCT00215254?

The interventions under investigation include: quetiapine (DRUG).

Who is sponsoring clinical trial NCT00215254?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.